Submitting a comment will take only a few minutes. Please comments to the Food and Drug Administration (FDA) on the Draft guidance entitled “Drug Products Labeled as Homeopathic, Guidance for FDA Staff and Industry” (Draft Guidance) issued December 20, 2017
The FDA is seeking to change the way they regulate homeopathy in the U.S. in a fashion that may put a large number of very important remedies at risk. We are trying to convince them that homeopathy has great value to healthcare (something you are your colleagues can speak to very well) and that they should not change their approach to regulatory oversight.
Specifically, we are requesting that the FDA revise their new Draft Guidance to reflect 1) that generic name homeopathic medicines are non-toxic and inherently safe when properly manufactured and labeled and used as directed, 2) that homeopathic medicines are not “new drugs” and 3) that the agency’s risk-based approach will be applied only to products IMPROPERLY called “homeopathic” on the label due either to manufacturing problems or improper labeling.
There is a website set up to make the process of leaving international comments extremely easy and very quick (under 60 seconds). Here is the link to that site: https://homeopathychoice.org/fda-comments-international/
We would love to get thousands of comments from your members and their associates. Peter W. Gold
American Institute of Homeopathy
172 West Main Street
Avon, CT 06001
Telephone: 860.674.1500
